XML 49 R24.htm IDEA: XBRL DOCUMENT v3.26.1
Income Taxes (Notes)
 6 Months Ended
Jun. 30, 2026
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block] INCOME TAXES
The Company’s provision for income taxes is based on the estimated annual effective tax rate, plus discrete items. The effective tax rates for the three and six months ended June 30, 2026 were 6% and (2)%, respectively. The effective tax rates for the three and six months ended June 30, 2025 were 428% and 1,082%, respectively. The effective tax rate for the six months ended June 30, 2025 was not meaningful due to pretax book income being near breakeven. The difference between the Company’s effective tax rates for the 2026 and 2025 periods and the U.S. statutory tax rate of 21% related primarily to foreign tax rate differentials, the impacts of foreign currency fluctuations at certain foreign subsidiaries, nondeductible expenses, valuation allowance, the impacts of U.S. investment tax credits (“ITCs”), and noncontrolling interest in our U.S. subsidiaries.
During the second quarter of 2026, the Company executed a public sale of the Fluence Class A shares, resulting in a pre-tax gain on sale of $186 million. The sale resulted in approximately $42 million of discrete tax expense for both the three and six months ended June 30, 2026. Additionally, the Company recognized discrete tax benefit of approximately $54 million associated with the Fluence sell-down transaction due to release of valuation allowance on U.S. capital losses. See Note 7—Investments in and Advances to Affiliates for additional information regarding the Fluence sell-down transaction.
For the six months ended June 30, 2026, the Company recorded discrete tax benefit of approximately $20 million associated with the merger of Cochrane into AES Andes and discrete tax expense of approximately $37 million resulting from allocations of losses to tax equity investors on renewables projects.
For the three and six months ended June 30, 2025, the Company recognized discrete tax expense of approximately $18 million and $44 million, respectively, resulting from allocations of losses to tax equity investors on renewables projects.